The distinctive nature of HER2-positive breast cancers.

H. Burstein

DOI:10.1056/NEJMP058197

Corpus ID: 26675265

The distinctive nature of HER2-positive breast cancers.

@article{Burstein2005TheDN,
  title={The distinctive nature of HER2-positive breast cancers.},
  author={H. Burstein},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 16},
  pages={
          1652-4
        }
}

H. Burstein

Published 2005

Medicine

The New England journal of medicine

The history of HER2 and trastuzumab treatment is a triumphal narrative of translational research. Dr. Harold Burstein writes that like all good stories, this one has a profound lesson: not all breast cancers are the same.

View PDF

Share This Paper

Top 3 of 361 Citations

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

N. Iqbal, Naveed IqbalMolecular biology international2014

290

Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR

D. Hicks, Sarah M Short, … R. WeilThe American journal of surgical pathology2006

245

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

Mark R. Trusheim, E. Berndt, F. DouglasNature Reviews Drug Discovery2007

427

Topics from this paper.

Explore Further: Topics Discussed in This Paper

Mammary Neoplasms

Paper Mentions

INTERVENTIONAL CLINICAL TRIAL

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Anti-HER2 sdAb

To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2 single domain antibody (sdAb) (Product Code Name: 99mTc-NM02 and 188Re-NM02) SPECT/CT imaging of HER2… Expand

Conditions	Breast Cancer
Intervention	Drug

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

July 2019 - September 2022

INTERVENTIONAL CLINICAL TRIAL

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal… Expand

Conditions	Breast Cancer
Intervention	Biological, Drug

NSABP Foundation Inc

February 2000 - March 2020

INTERVENTIONAL CLINICAL TRIAL

Overcoming Endocrine Resistance in Metastatic Breast Cancer

Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front… Expand